Literature DB >> 11721756

Cholecystokinin-Stimulated mebrofenin (99mTc-Choletec) hepatobiliary scintigraphy in asymptomatic postcholecystectomy individuals: assessment of specificity, interobserver reliability, and reproducibility.

B C Pineau1, W L Knapple, K M Spicer, L Gordon, M Wallace, W S Hennessy, R H Hawes, P B Cotton.   

Abstract

OBJECTIVES: Cholecystokinin-stimulated hepatobiliary scintigraphy (CCK-HBS) is a noninvasive method reported to be highly accurate in the diagnosis of sphincter of Oddi dysfunction. Our primary aim was to assess the specificity of CCK-HBS by evaluating its ability to exclude disease in 20 asymptomatic postcholecystectomy individuals. Secondary aims were to assess the interobserver reliability in scoring the CCK-HBS examinations between three blinded observers and to assess reproducibility of CCK-HBS repeated in the same individuals.
METHODS: Twenty asymptomatic postcholecystectomy individuals with normal liver serum chemistries underwent CCK-HBS on two separate occasions. Three nuclear medicine specialists read each CCK-HBS study in a blinded fashion.
RESULTS: There was good agreement between the three observers reading the same scans for both the first scan (kappa = 0.554) and the second scan (kappa = 0.507). There was poor agreement between the first and second scans on the same patient, read by the same nuclear medicine specialist (kappa = 0.062-0.385). The overall specificity of the CCK-HBS score was 77.5%; however, the specificity was only 60% when a true negative was defined as two negative CCK-HBS examinations.
CONCLUSIONS: Quantitative CCK-HBS is of poor specificity in asymptomatic postcholecystectomy individuals. Hence, it is of questionable value in excluding sphincter of Oddi dysfunction in patients suspected to suffer from this disorder.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11721756     DOI: 10.1111/j.1572-0241.2001.05266.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  9 in total

1.  Low yield of significant findings on endoscopic retrograde cholangiopancreatography in patients with pancreatobiliary pain and no objective findings.

Authors:  Timothy D Imler; Stuart Sherman; Lee McHenry; Evan L Fogel; James L Watkins; Glen A Lehman
Journal:  Dig Dis Sci       Date:  2012-06-02       Impact factor: 3.199

2.  "Characterization of basal hepatic bile...".

Authors:  Harvey A Ziessman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-03-11       Impact factor: 9.236

Review 3.  Biliary scintigraphy versus sphincter of Oddi manometry in patients with post-cholecystectomy pain: is it time to disregard the scan?

Authors:  James Toouli
Journal:  Curr Gastroenterol Rep       Date:  2005-05

Review 4.  Predicting and preventing post-ERCP pancreatitis.

Authors:  John Baillie
Journal:  Curr Gastroenterol Rep       Date:  2002-04

Review 5.  Sphincter of Oddi dysfunction: managing the patient with chronic biliary pain.

Authors:  Lana Bistritz; Vincent G Bain
Journal:  World J Gastroenterol       Date:  2006-06-28       Impact factor: 5.742

6.  Sphincter of Oddi Dysfunction.

Authors:  Stacy Menees; Grace H Elta
Journal:  Curr Treat Options Gastroenterol       Date:  2005-04

Review 7.  The diagnosis and management of Sphincter of Oddi dysfunction: a systematic review.

Authors:  Thomas C Hall; Ashley R Dennison; Giuseppe Garcea
Journal:  Langenbecks Arch Surg       Date:  2012-06-13       Impact factor: 3.445

8.  Management of patients with sphincter of Oddi dysfunction based on a new classification.

Authors:  Jia-Qing Gong; Jian-Dong Ren; Fu-Zhou Tian; Rui Jiang; Li-Jun Tang; Yong Pang
Journal:  World J Gastroenterol       Date:  2011-01-21       Impact factor: 5.742

9.  Characterization of basal hepatic bile flow and the effects of intravenous cholecystokinin on the liver, sphincter, and gallbladder in patients with sphincter of Oddi spasm.

Authors:  Gerbail T Krishnamurthy; Shakuntala Krishnamurthy; Randy D Watson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-10-22       Impact factor: 9.236

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.